KiroVAX 001

Drug Profile

KiroVAX 001

Alternative Names: KiroVAX001; TAPA-loaded DC vaccine - KiroVAX-001; TAPA-pulsed DC vaccine - KiroVAX-001; TAPA-pulsed dendritic cell vaccine - KiroVAX-001

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 28 Jul 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02709993)
  • 10 Mar 2016 Kiromic plans a phase I/II trial for Haematological malignancies (Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02709993)
  • 12 Feb 2015 Phase-I clinical trials in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top